---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-275815"
form_type: "8-K/A"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2026-06-18T20:06:18+00:00"
generated_at: "2026-06-18T20:15:07.452708+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# enGene cuts workforce 50%, grants CEO performance options tied to detalimogene BLA and FDA approval milestones

## Summary
- Workforce reduction of ~50% approved June 14; estimated cash restructuring costs $5.7-6.4M, non-cash stock comp $4.7-5.0M.
- Performance-based equity retention awards (options and RSUs) approved June 16, vesting upon FDA acceptance of detalimogene BLA (by Sep 30, 2027) and FDA approval (by Dec 31, 2028).
- CEO Ronald Cooper granted 400,000 performance-based options at $1.75/share, vesting 50% per milestone.
- Retention costs: up to $1.7M cash and $2.8M non-cash stock comp.
- Majority of expenses expected in H2 2026.

## SEC filing metadata
- accession: 0001193125-26-275815
- form_type: 8-K/A
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2026-06-18T20:06:18+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.05, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000119312526275815/0001193125-26-275815-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000119312526275815/engn-20260616.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-275815
- JSON: https://secwatch.observer/filing/0001193125-26-275815.json
- Plain text: https://secwatch.observer/filing/0001193125-26-275815.txt

## Key facts
- Restructurings & Charges
  enGene Therapeutics Inc. announced a restructuring with charges of approximately $5.7 to $6.4 million in cash, as well as approximately $4.7 million to $5.0 million in non-cash stock-based compensation expense (approximately 50% of its workforce).
  - Type: restructuring
  - Charge: approximately $5.7 to $6.4 million in cash, as well as approximately $4.7 million to $5.0 million in non-cash stock-based compensation expense
  - Headcount: approximately 50% of its workforce
  source text: equity retention awards, which will vest, if at all, upon the achievement of the Milestones, the Company now estimates that it will incur restructuring costs of approximately $5.7 to $6.4 million in cash, consisting primarily of employee severance, benefits, and other related costs, as well as approximately $4.7 million to $5.0 million in non-cash
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312526275815/0001193125-26-275815-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.